Previous 10 | Next 10 |
Revance Therapeutics, Inc. (Nasdaq: RVNC), a biotechnology company focused on innovative aesthetic and therapeutic offerings, today announced that the United States (U.S.) Food and Drug Administration (FDA) has issued a Complete Response Letter, or CRL, regarding the Biologics License A...
4 Top Health Care Stocks For Your Q4 Watchlist In times of volatility in the stock market, investors often turn to health care stocks . For the most part, this could be the case now given the current movement in the market. On one hand, earnings season seems to be kicking off on a h...
Shares of Revance Therapeutics (NASDAQ: RVNC) are up by a respectable 15.8% as of 11:08 a.m. EDT Wednesday morning. The biopharma's stock is regaining some of its lost ground after yesterday's unfortunate 22% dip. Shares of Revance hit the skids yesterday following the public di...
Gainers: Jasper Therapeutics JSPR +114%, Clarus Therapeutics (NASDAQ:CRXT) +45%, Alimera Sciences ALIM +19%, Revance Therapeutics RVNC +13%, Recursion Pharmaceuticals (NASDAQ:RXRX) +12%. Losers: NeuroOne Medical Technologies NMTC -25%, Ne...
NeuroBo Pharmaceuticals (NASDAQ:NRBO) +23% announces positive recommendation from independent data safety monitoring committee of phase 2/3 clinical trial of ANA001 in hospitalized patients with moderate to severe COVID-19 Jasper Therapeutics (NASDAQ:JSPR) +22% after bullish ca...
- BLA for DaxibotulinumtoxinA for Injection remains under FDA review - Revance Therapeutics, Inc. (Nasdaq: RVNC), a biotechnology company focused on innovative aesthetic and therapeutic offerings, responds to the public disclosure of its Form 483 pursuant to a Freedom of Inf...
Boston, Massachusetts--(Newsfile Corp. - October 12, 2021) - Block & Leviton is investigating Revance Therapeutics, Inc. (NASDAQ: RVNC) for potential securities law violations. Investors who have lost money in their Revance Therapeutics, Inc. investment should contact the firm to l...
-OPUL is an end-to-end, cloud-based payment platform designed to cultivate long-term customer relationships and optimize business operations for aesthetic practices- Revance Therapeutics, Inc. (Nasdaq: RVNC), a biotechnology company focused on innovative aesthetic and therap...
- ePoster and video presentation showcasing Phase 3 data to be shared - Revance Therapeutics, Inc. (Nasdaq: RVNC) a biotechnology company focused on innovative aesthetic and therapeutic offerings, today announced that it will present an ePoster with a video poster presentati...
- ePoster presentation highlights findings from a new post-hoc analysis evaluating efficacy and safety of the RHA® Collection - - Supports Revance’s commitment to ensuring safety and efficacy of aesthetic product portfolio among diverse patient populations - ...
News, Short Squeeze, Breakout and More Instantly...
Revance Therapeutics Inc. Company Name:
RVNC Stock Symbol:
NASDAQ Market:
Revance Therapeutics Inc. Website:
- Total net product revenue (DAXXIFY® and RHA® Collection) of $51.7 million, a YoY increase of 13%. - DAXXIFY® net revenue of $22.1 million, after a reduction of $2.0 million related to a consumer coupon program. - Toxin market share increased from 3.0% in Q4’23 to 3...
Conference Call Scheduled for Thursday, May 9, 2024 at 4:30 p.m. ET. Revance Therapeutics, Inc. (NASDAQ: RVNC), today announced that the company will release first quarter 2024 financial results on Thursday, May 9, 2024, after the close of market. Revance will host a corresponding confe...